血小板mTOR 是无菌免疫血栓的调节者
Frederik Denorme1,2, Irina Portier1, Heide Castro1
1Department of Emergency Medicine, Washington University, Saint Louis, MO (F.D., I.P., H.C., A.A., R.A.C.).
Arteriosclerosis, thrombosis, and vascular biology
|March 5, 2026
概括
拉巴胺素的血小板机械标 (mTOR) 驱动无菌免疫血栓形成,在中风和静脉血栓形成中至关重要. 抑制血小板mTOR可能为这些疾病提供一种安全的治疗策略.
科学领域:
- * 血液学和血栓症研究
- * 分子和细胞生物学
- * 炎症和免疫学
背景情况:
- *免疫血栓症涉及炎症和血栓性途径之间的复杂相互作用,导致缺血性中风和静脉血栓症.
- * 拉巴胺素的机械标 (mTOR) 是一种酶,在体外参与血小板信号传递和血栓稳定.
- * 血小板mTOR激活在衰老和炎症条件中升高,但其体内作用尚不清楚.
研究的目的:
- * 为了研究拉巴胺素 (mTOR) 血小板机械性标的体内功能.
- *评估血小板mTOR在血液静止,出血和血栓形成模型中的作用,包括无菌免疫血栓形成.
- * 评估向血小板mTOR的治疗潜力.
主要方法:
- * 一代患有血小板特异性mTOR缺乏症的小鼠.
- *评估血小板激活,血小板-白细胞相互作用,以及前凝性潜力.
- *使用血液静止,炎症出血,缺血性中风和静脉血栓形成的模型进行体内评估.
主要成果:
- *缺乏mTOR的血小板表现出减少的激活和前凝性潜力,与白细胞的相互作用减少.
- *血小板mTOR缺乏并没有影响血液静止或动脉血栓形成,但可以预防缺血性中风和静脉血栓形成.
- *在无菌免疫血栓模型中,没有血小板mTOR减少了血栓形成和炎症.
结论:
- *血小板mTOR对于无菌免疫血栓形成至关重要,这是缺血性中风和静脉血栓形成的关键因素.
- * 针对血小板mTOR是一个有前途的治疗策略,由于其在免疫血栓形成中的特殊作用,具有潜在的良好的安全性.
相关概念视频
Formation of the Platelet Plug
10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Structure and Function of Platelets
4.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.2K
Clot Retraction and Fibrinolysis
9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
PI3K/mTOR/AKT Signaling Pathway
6.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.0K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K


